# Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®

> **NCT01420211** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Medicine Greifswald** · enrollment: 45 (actual)

## Conditions studied

- Pharmacokinetics
- MRI
- Liver
- Drug Transporter
- Gd-EOB-DTPA

## Interventions

- **DRUG:** Primovist® 0,25 mmol/ml solution for injection
- **DEVICE:** MRI

## Key facts

- **NCT ID:** NCT01420211
- **Lead sponsor:** University Medicine Greifswald
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2011-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01420211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01420211, "Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01420211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*